Shiraz

Researchers are collecting detailed information about patients with venous thromboembolism (VTE), which includes blood clots in veins such as deep-vein thrombosis and pulmonary embolism. The project aims to improve doctors' understanding of VTE, especially in patients often excluded from clinical trials, like pregnant women, elderly individuals, cancer patients, and those with other complex health issues. The goal is to reduce deaths, clot recurrence, bleeding problems, and artery-related events by sharing this knowledge widely. The study involves gathering extensive data on each patient's health status, treatments, and outcomes during the first three months of therapy. This registry is available online to help doctors quickly find information on patients with similar medical profiles and make informed decisions about managing high-risk individuals. There are no specific interventions being tested; instead, the focus is on collecting real-world patient data. Participants provide informed consent and are followed for at least three years to monitor for new clot events and complications. Researchers track recurrences of VTE, bleeding episodes, and deaths, aiming to create tools that predict which patients are most at risk for problems. This ongoing data collection supports improving care and guiding treatment decisions for diverse patient groups over time.

Researchers are investigating how well a test called NiFFR, derived from CT angiography, can identify non-significant coronary artery lesions in patients with known or suspected chronic coronary syndrome. This study includes 250 patients who have at least one intermediate coronary lesion, defined as 50-70% narrowing of the artery. Participants were followed for one year to monitor for major cardiovascular events, known as MACE, which include cardiac-related death, acute coronary syndrome, unexpected revascularization, and hospitalization for heart problems. Participants had coronary computed tomography angiography (CCTA) to assess their coronary lesions and NiFFR values. Those with a NiFFR value greater than 0.80 underwent further evaluation. Clinical and lesion data, such as lesion location and vessel size, were collected using semi-automated software. Patients were monitored regularly during the one-year follow-up, with visits every three months and phone check-ins to track their health status. Throughout the study, detailed information was gathered including demographics, medical history, and vessel characteristics from registries. Researchers assessed the number of patients experiencing major adverse cardiovascular events and bleeding within one year. This close monitoring aimed to understand the ability of CTFFR to predict which coronary lesions are unlikely to cause significant problems, supporting better patient care and management.

The goal of this study is to evaluate Effectiveness and safety of Spartina® (Tirzepatide) in male or female participants with obesity and overweight. The main questions which are aimed to be answered: 1. Is Spartina® (Tirzepatide) effective in the treatment of obesity and overweight? 2. Is Spartina® (Tirzepatide) safe in the treatment of obesity and overweight? In this study, there is no comparison group. Participants receive Spartina® (Tirzepatide)

This research aims to compare the safety and effectiveness of ticagrelor alone versus dual antiplatelet therapy in patients with chronic coronary syndrome who undergo percutaneous coronary intervention (PCI). The study is a phase 4, single-center, randomized, double-blind trial focusing on patients receiving drug-eluting stents for revascularization of coronary artery disease. The goal is to evaluate major adverse cardiovascular events (MACE) and other outcomes over six months following PCI. Participants will be randomly assigned to one of two groups after diagnostic angiography but before stent insertion. One group will receive the standard dual antiplatelet therapy with aspirin 80 mg once daily and clopidogrel 75 mg once daily. The other group will receive ticagrelor 90 mg twice daily as a single antiplatelet agent. Both groups will start treatment with a loading dose before or at the time of PCI. The treatment period lasts for six months. During the study, participants will be monitored for cardiac events including stent thrombosis, myocardial infarction, and the need for revascularization. Researchers will also track bleeding events and all-cause mortality. Data will be collected through clinical assessments and a registry at the cardiology clinic. Safety and adherence will be carefully followed throughout the six-month period to evaluate the outcomes of each treatment strategy.